Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

ClinicalTrials.gov ID: NCT01980654

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01980654. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 10:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with Follicular Lymphoma (FL).

Study identification

NCT ID
NCT01980654
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pharmacyclics LLC.
Industry
Enrollment
80 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2013 (Type not available)
Primary completion
Nov 2017 (Actual)
Completion
Nov 2017 (Actual)
Last update posted
Apr 16, 2019

2013 – 2017

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
11
Facility City State ZIP Site status
Providence Saint Joseph Medical Center Burbank California 91505 —
City of Hope Duarte California 91010 —
UCLA Medical Center Los Angeles California 90095 —
Stanford University, Stanford Care Center Stanford California 94305 —
Southeastern Regional Medical Center Newnan Georgia 30265 —
Community Health Network Community Regional Cancer Center North Indianapolis Indiana 46256 —
Comprehensive Cancer Centers of Nevada Henderson Nevada 89074 —
Memorial Sloan-Kettering Cancer Center New York New York 10065 —
Weill Cornell Medical College New York-Presbyterian Hospital New York New York 10065 —
Mid-Ohio Oncology/ Hematology Inc Columbus Ohio 43219 —
Tennessee Oncology, PLLC The Sarah Cannon Research Institute Nashville Tennessee 37203 —
The University of Texas MD Anderson Cancer Center Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01980654, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 16, 2019 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.